查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球患者肿瘤组织移植模型市场规模,份额和趋势分析：按肿瘤类型(肺,胰腺),模型类型(大鼠,小鼠),用户(製药和生物製药公司,CRO,CDMO),细分市场预测2022-2030
市场调查报告书
商品编码
1171007

全球患者肿瘤组织移植模型市场规模,份额和趋势分析：按肿瘤类型(肺,胰腺),模型类型(大鼠,小鼠),用户(製药和生物製药公司,CRO,CDMO),细分市场预测2022-2030

Patient-derived Xenograft Model Market Size, Share & Trends Analysis Report By Tumor Type (Lung, Pancreatic), By Model Type (Rats, Mice), By End-user (Pharma & Biopharma Companies, CROs, CDMOs), And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 275 Pages | 商品交期: 2-10个工作天内

价格

全球吸入和鼻腔产品合同製造服务提供商市场规模到 2030 年将达到 6.614 亿美元，预计从 2022 年到 2030 年的复合年增长率为 12.8%。

癌症发病率的上升推动了对新治疗方案的需求，以及全球对个性化治疗的巨大需求正在推动市场增长。

本报告研究了全球患者肿瘤组织移植模型市场，并提供了包括市场前景、市场分析和竞争格局在内的全面信息。

内容

第一章调查方法及范围

  • 市场细分和范围
    • 肿瘤类型
    • 模型类型
    • 最终用户
    • 区域范围
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 模型详细信息
    • 商品流分析(模型 1)
    • 批量价格分析(模型 2)
  • 二级信息列表
  • 主要信息列表
  • 目的

第 2 章执行摘要

  • 市场前景

第 3 章患者肿瘤组织移植模型市场变量、趋势和范围

  • 市场系列展望
    • 母公司的市场前景
    • 相关/子公司市场前景
  • 描绘渗透率和增长前景
  • 市场动态
    • 市场驱动因素分析
      • 癌症在全球范围内继续增加
      • 增加癌症研发投资
      • 全球对个性化护理的需求
    • 市场製约因素分析
      • 用于个性化治疗的 PDX 模型成本高
      • 对动物模型的使用有严格的规定
    • 描绘渗透率和增长前景
    • COVID-19 的影响和恢復分析
    • 对主要交易和战略联盟的分析
    • 行业分析 - 波特五力分析
    • PESTLE 分析

第 4 章患者肿瘤组织移植模型市场：肿瘤类型细分分析

  • 患者肿瘤组织移植模型市场：定义和范围
  • 患者肿瘤组织移植模型市场：按肿瘤类型划分的市场份额分析(2021 年和 2030 年)
    • 肺癌
    • 胰腺癌
    • 前列腺癌
    • 乳腺癌
    • 其他癌症

第 5 章患者肿瘤组织移植模型市场：模型类型细分分析

  • 患者肿瘤组织移植模型市场：定义和范围
  • 患者肿瘤组织移植模型市场：按模型类型划分的市场份额分析(2021 年和 2030 年)
    • 鼠标
    • 大鼠

第 6 章患者肿瘤组织移植模型市场：最终用户细分分析

  • 患者肿瘤组织移植模型市场：定义和范围
  • 患者肿瘤组织移植模型市场：最终用户市场份额分析(2021 年和 2030 年)
    • 製药和生物製药公司
    • 学术和研究机构
    • CRO□CDMO

第 7 章患者肿瘤组织移植模型市场：区域分析

  • 患者肿瘤组织移植模型：区域市场份额分析(2021 年和 2030 年)
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 意大利
    • 西班牙
      • 西班牙患者肿瘤组织移植模型市场(百万美元)(2018-2030 年)
    • 法国
      • 法国患者肿瘤组织移植模型市场(百万美元)(2018-2030 年)
  • 亚太地区
    • 亚太地区患者肿瘤组织移植模型市场(百万美元)(2018-2030 年)
    • 中国
    • 印度
      • 印度患者肿瘤组织移植模型市场(百万美元)(2018-2030 年)
    • 日本
      • 日本患者肿瘤组织移植模型市场，2018-2030 年(百万美元)
    • 澳大利亚
      • 澳大利亚患者肿瘤组织移植模型市场(百万美元)(2018-2030 年)
  • 拉丁美洲
    • 拉丁美洲患者肿瘤组织移植模型市场(百万美元)(2018-2030 年)
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 南阿拉伯
    • 阿拉伯联合酋长国

第八章竞争格局

  • 患者肿瘤组织移植模型：公司市场份额分析(2021 年和 2030 年)
  • 公司简介
    • Charles River Laboratories
    • The Jackson Laboratory
    • Crown Bioscience
    • Altogen Labs
    • Envigo
    • WuxiAppTec
    • Oncodesign
    • Hera Biolabs
    • XenTech
    • Abnova Corporation
Product Code: GVR-4-68040-002-0

Patient-derived Xenograft Model Market Growth & Trends:

The global patient-derived xenograft model market size is expected to reach USD 661.4 million by 2030, registering a CAGR of 12.8% over the forecast years according to a new report by Grand View Research, Inc. Growing burden of cancer, which is promoting the demand for new treatment options, along with significant demand for personalized therapies worldwide will boost the growth of the industry. Patient-derived Xenograft (PDX) models have garnered increasing awareness during the past decade. These types are typically characterized by the introduction of fresh immunodeficient mice with patient-derived tumor tissues. These models have been used with efficacy in preclinical studies to identify prospective biomarkers for drug response and resistance, as well as to monitor the development of tumors in therapy response. The concept of a co-clinical study, which involves using several models at once-referred to as "Avatar models"-has recently grown in popularity and has been expanded to incorporate PDX models.

Moreover, PDX models were used in a few prospective trials to direct therapeutic therapy decisions for a limited number of patients with confirmed extended survival. The COVID-19 pandemic had a negative impact on the industry. It disrupted the clinical trials and also reduced the productivity of pharmaceutical & biopharmaceutical companies. According to research by Avantor Sciences, 70% of global clinical trials were disrupted as of July 2020. 369 trials related to oncology had been delayed in the USA alone, central nervous system trials at 223, gastrointestinal trials at 116, and cardiovascular trials at 99. Despite COVID-19, the rising number of cancer cases & increased R&D activities by pharmaceutical companies will contribute to the growth of the market. For instance, as per the GLOBOCAN Report 2020, 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020. The majorly impacted cancers were breast, lung, colorectal, and prostate cancer.

Patient-derived Xenograft Model Market Report Highlights:

  • The breast cancer segment dominated the industry in 2021 due to arise in the cases of breast cancer driving the growth of the market
  • For instance, female breast cancer is expected 2.3 million new cases & has surpassed lung cancer as the most prevalent disease diagnosed
  • The mice model type segment held the highest revenue share in 2021 due to factors, such as the increasing use of the mice model for cancer treatment and ease of manipulation & procurement
  • The CROs & CDMOs end-user segment accounted for the largest share in 2021. The segment is also anticipated to witness the fastestCAGRover the forecast period
  • A growing number of pharmaceutical companies are outsourcing their preclinical studies to CROs & CDMOs, which, in turn, is driving the growth of this segment
  • North America was the largest region in 2021 due to a high number of research studies in the region, increased funding for preclinical research, and demand for innovative therapies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Tumor Type
    • 1.1.2. Model Type
    • 1.1.3. End User
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Volume price analysis (Model 2)
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2
    • 1.9.3. Objective 3
    • 1.9.4. Objective 4

Chapter 2. Executive Summary

  • 2.1. Market Outlook

Chapter 3. Patient-Derived Xenograft Model Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Growing burden of cancer across the globe
      • 3.3.1.2. Increasing R&D investment for cancer research
      • 3.3.1.3. Demand for personalized therapies worldwide
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. High cost of personalized PDX models
      • 3.3.2.2. Stringent regulations towards the use of animal models
    • 3.3.3. Penetration & Growth Prospect Mapping
    • 3.3.4. Covid-19 Impact & Recovery Analysis
    • 3.3.5. Major Deals and Strategic Alliances Analysis
    • 3.3.6. Industry Analysis - Porter's
    • 3.3.7. PESTLE Analysis

Chapter 4. Patient-Derived Xenograft Model Market: Tumor Type Segment Analysis

  • 4.1. Patient-Derived Xenograft Model Market: Definition & Scope
  • 4.2. Patient-Derived Xenograft Model Market: Tumor Type Market Share Analysis, 2021 & 2030
    • 4.2.1. Lung Cancer
      • 4.2.1.1. Lung Cancer Market, 2018 - 2030 (USD Million)
    • 4.2.2. Pancreatic Cancer
      • 4.2.2.1. Pancreatic Cancer Market, 2018 - 2030 (USD Million)
    • 4.2.3. Prostate Cancer
      • 4.2.3.1. Prostate Cancer Market, 2018 - 2030 (USD Million)
    • 4.2.4. Breast Cancer
      • 4.2.4.1. Breast Cancer Market, 2018 - 2030 (USD Million)
    • 4.2.5. Other Cancer
      • 4.2.5.1. Other Cancer Market, 2018 - 2030 (USD Million)

Chapter 5. Patient-Derived Xenograft Model Market: Model Type Segment Analysis

  • 5.1. Patient-Derived Xenograft Model Market: Definition & Scope
  • 5.2. Patient-Derived Xenograft Model Market: Model Type Market Share Analysis, 2021 & 2030
    • 5.2.1. Mice
      • 5.2.1.1. Mice Market, 2018 - 2030 (USD Million)
    • 5.2.2. Rats
      • 5.2.2.1. Rats Market, 2018 - 2030 (USD Million)

Chapter 6. Patient-Derived Xenograft Model Market: End-user Segment Analysis

  • 6.1. Patient-Derived Xenograft Model Market: Definition & Scope
  • 6.2. Patient-Derived Xenograft Model Market: End User Market Share Analysis, 2021 & 2030
    • 6.2.1. Pharmaceutical & Biopharmaceutical Companies
      • 6.2.1.1. Pharmaceutical & Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)
    • 6.2.2. Academic & Research Institutes
      • 6.2.2.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
    • 6.2.3. CROs & CDMOs
      • 6.2.3.1. CROs & CDMOs Market, 2018 - 2030 (USD Million)

Chapter 7. Patient-Derived Xenograft Model Market: Regional Analysis

  • 7.1. Patient-Derived Xenograft Model: Regional market share analysis, 2021 & 2030
  • 7.2. North America
    • 7.2.1. U.S. Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.3.4. Italy
      • 7.3.4.1. Italy Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.3.5. Spain
      • 7.3.5.1. Spain Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
    • 7.3.6. France
      • 7.3.6.1. France Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.4.3. India
      • 7.4.3.1. India Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
    • 7.4.4. Japan
      • 7.4.4.1. Japan Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Patient-Derived Xenograft Model Market, 2018 - 2030(USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Mexico Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Argentina Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.6.3. South Arabia
      • 7.6.3.1. South Africa Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Patient-Derived Xenograft Model Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Patient-Derived Xenograft Model: Company market share analysis, 2021 & 2030
  • 8.2. Company Profiles
    • 8.2.1. Charles River Laboratories
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Service benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. The Jackson Laboratory
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Service benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Crown Bioscience
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Service benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Altogen Labs
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Service benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Envigo
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Service benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. WuxiAppTec
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Service benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Oncodesign
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Service benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Hera Biolabs
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Service benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. XenTech
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Service benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Abnova Corporation
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Service benchmarking
      • 8.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary sources
  • Table 2 List of Abbreviations

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Volume price analysis
  • Fig. 9 Patient-derived xenograft model market snapshot (2021)
  • Fig. 10 Patient-derived xenograft model market segmentation
  • Fig. 11 Heat map analysis
  • Fig. 12 Parent market outlook
  • Fig. 13 Ancillary market outlook
  • Fig. 14 Penetration & growth prospect mapping
  • Fig. 15 Market driver relevance analysis (Current & future impact)
  • Fig. 16 Market restraint relevance analysis (Current & future impact)
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 19 Patient-derived xenograft model market tumor type outlook: Segment dashboard
  • Fig. 20 Patient-derived xenograft model market: tumor type movement analysis
  • Fig. 21 Lung cancer market, 2018 - 2030 (USD Million)
  • Fig. 22 Pancreatic cancer market, 2018 - 2030 (USD Million)
  • Fig. 23 Prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 24 Breast cancer market, 2018 - 2030 (USD Million)
  • Fig. 25 Other cancer market, 2018 - 2030 (USD Million)
  • Fig. 26 Patient-derived xenograft model market model type outlook: Segment dashboard
  • Fig. 27 Patient-derived xenograft model market: model type movement analysis
  • Fig. 28 Mice market, 2018 - 2030 (USD Million)
  • Fig. 29 Rats market, 2018 - 2030 (USD Million)
  • Fig. 30 Patient-derived xenograft model market end-user outlook: Segment dashboard
  • Fig. 31 Patient-derived xenograft model market: End user movement analysis
  • Fig. 32 Pharmaceutical & Biopharmaceutical companies market, 2018 - 2030 (USD Million)
  • Fig. 33 Academic & research institutes market, 2018 - 2030 (USD Million)
  • Fig. 34 CROs & CDMOs market, 2018 - 2030 (USD Million)
  • Fig. 35 Regional market: Key takeaways
  • Fig. 36 Patient-derived xenograft model market: Regional movement analysis
  • Fig. 37 North America. market, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 39 Canada market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe market, 2018 - 2030 (USD Million)
  • Fig. 41 U.K. market, 2018 - 2030 (USD Million)
  • Fig. 42 Germany market, 2018 - 2030 (USD Million)
  • Fig. 43 France market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy market, 2018 - 2030 (USD Million)
  • Fig. 45 Spain market, 2018 - 2030 (USD Million)
  • Fig. 46 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 47 Japan market, 2018 - 2030 (USD Million)
  • Fig. 48 China market, 2018 - 2030 (USD Million)
  • Fig. 49 India market, 2018 - 2030 (USD Million)
  • Fig. 50 Australia market, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 53 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 55 MEA market, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 57 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 58 UAE market, 2018 - 2030 (USD Million)